REFERENCES
- Eschbach JVV, Kelly MR, Haley NR, Abels RI, Adamson JVV. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158–63.
- Zachée P. Controversies in selection of epoetin dosages. Drugs 1995; 49: 536–47.
- Bommer J, Barth H-P, Zeier M, Mandelbaum A, Bommer G, Ritz E, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991; 88: 136–43.
- McMahon LP, Dawbom JK. Experience with low dose intravenous and subcutaneous administration or recom-binant human erythropoietin. Am J Nephrol 1990; 10: 404–8.
- Hörl WH. Optimal route of administration of erythro-poietin in chronic renal failure: intravenous versus subcutaneous. Acta Haematol 1992; 87: 16–19.
- Macdougall IC, Davies ME, Hutton RD, Cavill I, Lewis NP, Coles GA, et al. The treatment of renal anemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 1990; 5: 950–5.
- Grannolleras C, Branger B, Shaldon S, Nonnast-Daniel B, Koch KM, Pollock M, et al. Subcutaneous erythro-poietin: a comparison of daily and thrice weekly administration. Contrib Nephrol 1991; 88: 144–8.
- Slingeneyer A, Faller B, Laroche B, Ehmer B, Mion C. Self administered daily subcutaneous recombinant hu-man erythropoietin: an open randomized dose finding study in ESRD patients receiving peritoneal dialysis. Contrib Nephrol 1991; 88: 159–68.
- Stockenhuber F, Loibl U, Gottsauner-Wolf M, Jahn C, Manker W, Meisl TF, et al. Pharmacokinetics and dose response after intravenous and subcutaneous adminis-tration of recombinant human erythropoietin in patients on regular hemodialysis treatment or continuous ambu-latory peritoneal dialysis. Nephron 1991; 59: 399–402.
- Caravaca F, Pizarro JL, Arrobas M, Cubero JJ, Carcia MC, Perez-Miranda M. Antiplatelet therapy and devel-opment of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 1994; 45: 845–51.
- Salmonsen T, Danielson B, Wikstrom B. The pharma-cokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990; 29: 709–13.
- Jensen JD, Jensen LW, Madsen JR. The pharmaco-kinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol 1994; 46: 333–7.
- Macdougall IC, Jones JM, Robinson MI, Miles JB, Coles GA, Williams JD. Subcutaneous erythropoietin therapy: Comparison of three different sites of injection. Contrib Nephrol 1991; 88: 152–6.
- Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swamer JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981; 4: 366–76.
- Thow J, Home P. Insulin injection technique. Br Med J 1990; 301: 3–4.
- Vaag A, Pedersen DK, Lauritzen M, Hildebrandt P. Beck-Nielsen H. Intramuscular versus subcutaneous injection of unmodified insulin: consequences for blood glucose control in patients with type I diabetes mellitus. Diabet Med 1990; 7: 335–43.
- Kroon C, De Boer A, Koon JM, Schoenmaker HC, Vd. Meer FJM, Cohen AF. Influence of the skin-fold thickness on heparin absorption. Lancet 1991; 337: 945–6.
- Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694–99.